Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Genitourinary 1Gastrointestinal 1Endocrine 1Classical hematology 1Breast 1

Conditions

Castrate Resistance Prostate Cancer 1

Interventions

Docetaxel 409pembrolizumab 332Prednisone 290enzalutamide 285Gemcitabine 274Radiotherapy 270Magnetic Resonance Spectroscopy 269Nivolumab 253Abiraterone Acetate 218Cisplatin 212Leuprolide 195Radiosurgery 192Sunitinib 188Carboplatin 161Androgen Antagonists 156bicalutamide 152Specimen Handling 149Goserelin 149Ipilimumab 131Paclitaxel 126acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 122apalutamide 118Cyclophosphamide 117Bevacizumab 116Sorafenib 114Everolimus 111abiraterone 108cabozantinib 105atezolizumab 105Biopsy 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Deamino Arginine Vasopressin × Genitourinary × Clear all
NCT04113005 2019-10-02

Safety and Tolerability Analysis of Combining Desmopressin With Docetaxel for the Treatment of Castration-Resistant Prostate Cancer

Sunnybrook Health Sciences Centre

Phase EARLY_PHASE1 Unknown
10 enrolled
Genitourinary

Castrate Resistance Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡